Translational Advances in Gynecologic Cancers1st Edition PDF
Translational Advances in Gynecologic Cancers straddles the bench and bed divide by highlighting important and interesting research that is translatable to the clinic. The contents of this book cover the entire spectrum, from promising laboratory based research, to clinical trial efforts. Further, new therapeutic indications based upon randomized phase III trials are also included.
Clinicians will learn about lab-based science that is about to enter the clinic, along with the rationale behind translational endpoints in trials. Researchers will be able to identify and understand the clinical needs of patients with these types of tumors to improve their research focus.
Provides a comprehensive description of all evolving translational gynecologic cancer research for clinicians
Identifies knowledge gaps to inform the next research direction
Ties together clinical research and patient needs to help both the researcher and clinician
Addresses genomics, new target therapies, novel tools, and more for ovarian, endometrial, and cervical cancer
About the Author
Dr. Michael Birrer is a Professor of Medicine at Harvard Medical School, the Director of Medical Gynecologic Oncology, Gynecologic Oncology Research Program, and the Gellete Center for Gynecologic Oncology at Massachusetts General Hospital (MGH) in Boston, Massachusetts. He is also a practicing physician at MGH.
The Birrer laboratory has had a long-term interest in characterizing the molecular origins of gynecologic cancers. This interest includes the identification and characterization of mutations in oncogenes and tumor suppressor genes within cancers of the ovary, endometrial and cervix. In addition, they have extensively characterized the differential gene expression in these tumors. The role of these genes in the development of these cancers has been tested using in vitro and in vivo model systems. The laboratory is focused on using the genomic events characterized in these cancers to produce translational science endeavors, which will result in clinically important discoveries. These genomic abnormalities form the basis for early detection assays, prevention strategies, and novel therapeutic approaches. Dr. Birrer’s laboratory focuses on bench-to-bedside-and-back-again approaches to produce clinically relevant strategies to better manage women with these cancers.
MD, Department of Medicine, Division of Hematology-Oncology, Massachusetts General Hospital, Boston, MA, USA